The Challenge to Search for New Nervous System Disease Biomarker Candidates: the Opportunity to Use the Proteogenomics Approach

Nery, Thais Guimarães Martins; Silva, Esdras Matheus; Tavares, Raphael; Passetti, Fábio

doi:10.1007/s12031-018-1220-1

Cited by 9 publications

(2 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the success of therapeutic strategies for neurodegenerative diseases including PD and AD is still limited. In fact, existing clinical drugs are not effective and only keep the patient's health from degrading [3]. Furthermore, current treatments are linked to significant social, economic, and personal costs [4].…”

Section: Introductionmentioning

confidence: 99%

Natural Polysaccharides as Preventive and Therapeutic Horizon for Neurodegenerative Diseases

et al. 2021

View full text Add to dashboard Cite

Neurodegenerative diseases are a serious and widespread global public health burden amongst aging populations. The total estimated worldwide global cost of dementia was US$818 billion in 2015 and has been projected to rise to 2 trillion US$ by 2030. While advances have been made to understand different neurodegenerative disease mechanisms, effective therapeutic strategies do not generally exist. Several drugs have been proposed in the last two decades for the treatment of different types of neurodegenerative diseases, with little therapeutic benefit, and often with severe adverse and side effects. Thus, the search for novel drugs with higher efficacy and fewer drawbacks is an ongoing challenge in the treatment of neurodegenerative disease. Several natural compounds including polysaccharides have demonstrated neuroprotective and even therapeutic effects. Natural polysaccharides are widely distributed in plants, animals, algae, bacterial and fungal species, and have received considerable attention for their wide-ranging bioactivity, including their antioxidant, anti-neuroinflammatory, anticholinesterase and anti-amyloidogenic effects. In this review, we summarize different mechanisms involved in neurodegenerative diseases and the neuroprotective effects of natural polysaccharides, highlighting their potential role in the prevention and therapy of neurodegenerative disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Natural Polysaccharides as Preventive and Therapeutic Horizon for Neurodegenerative Diseases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Neurodegenerative disorders (NDs) are highly prevalent brain diseases among the aging population, and no definitive cures exist [1][2][3]. Appropriate biomarkers are not available to diagnose NDs at an early stage, and it may be far too late to treat the disease effectively after symptoms appear.…”

Section: Introductionmentioning

confidence: 99%

Preclinical evaluation of a microtubule PET ligand [11C]MPC-6827 in tau and amyotrophic lateral sclerosis animal models

et al. 2022

View full text Add to dashboard Cite

Background: Microtubules are abundant in brain and their malfunctioning occurs in the early to advanced stages of neurodegenerative disorders. At present there is no in vivo test available for a definitive diagnosis of most of the neurodegenerative disorders.Herein, we present the microPET imaging of microtubules using our recently reported Positron Emission Tomography (PET) tracer, [ 11 C]MPC-6827, in transgenic mice models of tau pathology (rTg4510) and amyotrophic lateral sclerosis pathology (SOD1*G93A) and compared to corresponding age matched controls. Methods: Automated synthesis of [ 11 C]MPC-6827 was achieved in a GE-FX2MeI/FX2M radiochemistry module. In vivo PET imaging studies of [ 11 C]MPC-6827 (3.7+0.8 MBq)were performed in rTg4510 and SOD1*G93A mice groups and their corresponding littermates (n=5 per group). Dynamic PET images were acquired using a microPET Inveon system (Siemens, Germany) at 55 minutes for rTg4510 and 30 minutes for SOD1*G93A and corresponding controls. PET images were reconstructed using the 3D-OSEM algorithm and analyzed using VivoQuant version 4 (Invicro, MA). Tracer uptake in ROIs that included whole brain was measured as %ID/g over time to generate standardized uptake values (SUV) and time-activity curves (TACs).Results: [ 11 C]MPC-6827 exhibit a trend of lower tracer binding in mouse models of Alzheimer's disease (tau pathology, line rTg4510) and Amyotrophic Lateral Sclerosis (line SOD1*G93A) compared to wild type littermates. Conclusions:Our finding indicates a trend of loss of microtubule binding of [ 11 C]MPC-6827 in the whole brain of AD and ALS transgenic mice models compared to control mice.The pilot studies described herein show that [ 11 C]MPC-6827 could be used as a PET ligand for preclinical and human brain imaging of Alzheimer's disease, ALS and other neurodegenerative diseases.

show abstract

SWATH Mass Spectrometry Applied to Cerebrospinal Fluid Differential Proteomics: Establishment of a Sample-Specific Method

Anjo

Santa

Manadas

2019

Methods in Molecular Biology

View full text Add to dashboard Cite

The Challenge to Search for New Nervous System Disease Biomarker Candidates: the Opportunity to Use the Proteogenomics Approach

Cited by 9 publications

References 143 publications

Natural Polysaccharides as Preventive and Therapeutic Horizon for Neurodegenerative Diseases

Natural Polysaccharides as Preventive and Therapeutic Horizon for Neurodegenerative Diseases

Preclinical evaluation of a microtubule PET ligand [11C]MPC-6827 in tau and amyotrophic lateral sclerosis animal models

SWATH Mass Spectrometry Applied to Cerebrospinal Fluid Differential Proteomics: Establishment of a Sample-Specific Method

Contact Info

Product

Resources

About